All Stories

  1. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
  2. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
  3. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
  4. Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers
  5. Single and Multiple Dose PK–PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers
  6. Immunological safety assessment of a single and repeated intra-articular administration of xenogeneic equine umbilical cord mesenchymal stem cells under field conditions in young healthy dogs: A randomized double-blind placebo-controlled study
  7. Effect of Obesity and Gastric Surgery on Omeprazole oral absorption and pharmacokinetics
  8. Immune Response and Reactogenicity After Immunization With a Suboptimal Two-Dose mRNA Vaccine Followed by a Full Vaccination With a Standard mRNA Vaccine Compared to a Prime-Boost Regimen of a Standard mRNA Vaccine: A Multicenter Cohort Study
  9. Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study
  10. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
  11. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
  12. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
  13. Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department
  14. Chiral bioanalytical methods in bioequivalence studies of intravenous vs. oral formulations of ibuprofen
  15. Clinical Trial on Glimepiride 2mg Single Oral Dose in Healthy Volunteers: Need for Preventive Management of Hypoglycaemia
  16. European survey on national harmonization in clinical research
  17. Effect of enantiomerism on the bioequivalence of a new ibuprofen 600‐mg tablet formulation obtained by roller compaction
  18. European survey on national training activities in clinical research
  19. Rational Design, Structure–Activity Relationship, and Immunogenicity of Hypoallergenic Pru p 3 Variants
  20. Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect?
  21. Adverse drug reactions in neonates: a prospective study
  22. Teaching of Pharmacology, clinical Pharmacology and Therapeutics in Spanish Medical Schools. preliminary results
  23. Scren: Spanish Research Netwok; one-Year Experience
  24. Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy
  25. Integración de la tramitación del contrato de ensayo clínico en el plazo de evaluación por el Comité de Ética de Investigación Clínica. Estudio piloto MINT&R®-cec
  26. Response Letter to Malafarina and Colleagues
  27. FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies
  28. Truncated AUC in the Evaluation of Fluconazole Bioequivalence
  29. Bioequivalence Study of Two Different Tablet Formulations of Carvedilol in Healthy Volunteers
  30. Comparative Bioavailability/Bioequivalence of Two Different Sertraline Formulations
  31. Truncated Area under the Urinary Excretion Rate Curve in the Evaluation of Alendronate Bioequivalence after a Single Dose in Healthy Volunteers
  32. Risk of Cerebrovascular Accident Associated with Use of Antipsychotics: Population-Based Case-Control Study
  33. Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol
  34. Recomendaciones para el tratamiento del dolor neuropático
  35. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale
  36. Effects ofHypericum perforatumon Ivabradine Pharmacokinetics in Healthy Volunteers: An Open-Label, Pharmacokinetic Interaction Clinical Trial
  37. Lack of Pharmacokinetic Interaction Between Omeprazole or Lansoprazole and Ivabradine in Healthy Volunteers: An Open-Label, Randomized, Crossover, Pharmacokinetic Interaction Clinical Trial
  38. Effect of drug-test interactions on length of hospital stay
  39. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers
  40. A new high-absorption-rate Paracetamol 500-mg formulation: a comparative bioavailability study in healthy volunteers
  41. Effect of adverse drug reactions on length of stay in surgical intensive care units
  42. Pharmacokinetic Study of a New Ibuprofen 600mg plus Codeine 30mg Combination versus Ibuprofen or Codeine Alone in Single Oral Doses in Healthy Volunteers
  43. Comparative Single-Dose Bioavailability Study of Two Oral Formulations of Ibuprofen in Healthy Volunteers
  44. Modification of Albumin Use Pattern After an Educational Intervention
  45. Acute myocardial infarction associated with sildenafil
  46. Use of albumin in two Spanish university hospitals
  47. Use of Intravenous Omeprazole in a University Hospital
  48. Adverse Drug Reactions in a Cardiology Department
  49. Physical dependence to morphine diminishes the interferon response in mice
  50. Inmunoferon (Am3) Enhances the Activities of Early–Type Interferon Inducers and Natural Killer Cells.